Roche considers direct-to-patient sales in US to bypass middlemen and reduce costs

Roche Holding AG is considering selling drugs directly to US patients, bypassing middlemen like pharmacy benefit managers (PBMs). CEO Thomas Schinecker said direct sales would reduce costs "quite quickly" and eliminate intermediaries that take a significant portion of profits. The move would follow recent direct-to-patient sales by Pfizer, Lilly, and Novo Nordisk.